<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1007601.ref049">
 <label>49</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Benedict</surname>
   <given-names>A</given-names>
  </name>, 
  <name>
   <surname>Bansal</surname>
   <given-names>N</given-names>
  </name>, 
  <name>
   <surname>Senina</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Hooper</surname>
   <given-names>I</given-names>
  </name>, 
  <name>
   <surname>Lundberg</surname>
   <given-names>L</given-names>
  </name>, 
  <name>
   <surname>de la Fuente</surname>
   <given-names>C</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection</article-title>. 
  <source>Front Microbiol</source>. 
  <year>2015</year>;
  <volume>6</volume>:
  <fpage>676</fpage> Epub 2015/07/29. 
  <pub-id pub-id-type="doi">10.3389/fmicb.2015.00676</pub-id> ; PubMed Central PMCID: PMCPmc4495339.
  <?supplied-pmid 26217313?>
  <pub-id pub-id-type="pmid">26217313</pub-id>
 </mixed-citation>
</ref>
